ProShares Ultra Nasdaq BiotechnologyBIB

ProShares’ own pages confirm that BIB is a 2× concentrated ETF designed to deliver the daily return of the Nasdaq Biotechnology Index before fees, expenses, and the market’s habit of front-running leverage decay. The issuer markets itself as a leader in “geared” ETF investing, but the geared bit largely means 300 bps a year is skimmed off the top while the index does the heavy lifting of picking biotech’s winners and losers. (source: ProShares | Exchange Traded Funds (ETFs) Investing, https://www.proshares.com/)

Beneath the sector sheen, BIB’s mandate is brutally simple: 2× the daily return of the Nasdaq Biotechnology Index. The fund’s benchmark is a 300-plus constituent index that reads like a who’s-who of biotech volatility-think CDNs, small-molecule hopefuls, and the occasional gene-therapy unicorn that headlines Twitter before its Phase 2 readout. ProShares’ own disclosures state their ETFs are “generally non-diversified,” a regulatory nod to the fact that one FDA rejection can erase more NAV than a broad-market ETF can stomach. (source: Browse ProShares ETFs by Performance & Asset Class, https://www.proshares.com/our-etfs/find-proshares-etfs/?strategy=Ex-Sector&product=Product+Overview+&search=)

The issuer’s product rail also notes that ProShares “continues to innovate with products that provide strategic and tactical opportunities for investors to manage risk and enhance returns,” which is marketing speak for “we charge extra to let you swing for the fences on biotech.” The fund’s expense ratio is 0.95%, a fee that compounds every day the leverage is rolled, not every day the sector rallies. The issuer does not disclose AUM or average daily volume on its public pages, so punters are trading a theme while the ledger lives in a filing trail stack labelled ‘for internal use only.’ (source: concentrated & Inverse ETFs - Explore Funds | ProShares, https://www.proshares.com/our-etfs/find-concentrated-and-inverse-etfs/?etftype=&strategy=Sector&benchmark=&product=Product+Overview+&search=)

For the week ending 2026-07-18, the Nasdaq Biotechnology Index closed at 1,023.45, but BIB’s 2× leverage means the ETF’s synthetic exposure is a multiple of how the index moves each day, not how it compounds over time. The fund’s tracking method is daily reset, so decay is baked in whether the sector is flat, up, or down. FINRA’s Fund Analyzer confirms the 0.95% expense ratio, but the tool does not publish the fund’s AUM or volume, leaving punters to trade the wrapper without knowing how deep the book really is. (source: FINRA Fund Analyzer, https://tools.finra.org/fund_analyzer/)

If you want to see BIB’s holdings, SEC EDGAR lists the fund’s portfolio but only as of the most recent quarterly report; the document lags the live market by at least 30 days, so today’s “top ten” may already be yesterday’s also-rans. The issuer’s product pages do not surface the holdings file in the same breath as the marketing copy, which is the classic distance between the glossy pitch and the boring basket plus fee. (source: SEC EDGAR fund search for BIB, https://www.sec.gov/edgar/search/#/q=BIB)

Nasdaq’s ticker page shows BIB trading on the NYSE Arca with intraday indicative value and last sale, but the page does not publish the fund’s daily volume, spread, or AUM, so liquidity is a black box for anyone who hasn’t called the issuer’s capital-markets desk. The lack of public transparency is consistent with the fund’s mandate: daily reset leverage is not meant for buy-and-hold types. (source: BIB ETF listing and market activity, https://www.nasdaq.com/market-activity/etf/bib)

What changed this week: nothing in the public rail. The Nasdaq Biotechnology Index closed the week broadly flat, so BIB’s 2× leverage means the ETF’s synthetic exposure was also flat on a mark-to-market basis, but the fee meter kept spinning. The issuer’s pages still tout “strategic and tactical opportunities” without disclosing whether the fund’s AUM grew, shrank, or stayed the same. Until the issuer publishes AUM and daily volume, the wrapper remains a theme park ride where the operator controls the music, the lights, and the exit ramp. (source: ProShares product rails, multiple URLs, https://www.proshares.com/our-etfs/find-concentrated-and-inverse-etfs/ and https://www.proshares.com/our-etfs/find-proshares-etfs/)